Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Abstract

This study demonstrates that CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. Our approach expands the spectrum of antigens available for redirected T-cell therapy against solid malignancies and offers a promising new avenue for liver cancer immunotherapy. Clin Cancer Res; 23(2); 478-88. ©2016 AACR.

In situ antitumor vaccination: Targeting the tumor microenvironment

“…Recently, Nishio et al (2014) have overcome the obstacle through inoculating intratumorally with an armed oncolytic virus which effectively attracted CAR‐T cells to the tumor site. In addition, it is reported that directly intratumorally administered CAR‐T cells could generate a potent and long‐lasting antitumor immune response (Adusumilli et al, 2014; H. Liu et al, 2017; Pituch et al, 2018; Priceman et al, 2018). Several related clinical trials of intratumoral immunization are in research phase (Table 5).…”

Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives

“…Other groups are exploring the possibility of local delivery, to enhance tumor killing and to reduce toxicity. Indeed, it has been shown that regional administration of anti-AFP or anti-CEA CAR T cells was equally effective or even superior to a systemic administration in xenograft models of peritoneal carcinomatosis (106,107), and the delivery of CAR T cells through percutaneous hepatic artery infusions has shown to be safe and clinically active in patients with CEA-expressing liver metastases (108). A different approach to favor the localization into the tumor site consists in the administration of CAR T cells overexpressing tumorspecific chemokine receptors enhancing their capacity of reaching the tumor tissues (109).…”

Predictive and therapeutic biomarkers in chimeric antigen receptor T‐cell therapy: A clinical perspective

“…The results of several clinical trials testing CARs and transgenic TCRs, particularly in patients with hematological malignancies, demonstrated that these engineered T cells are robust tools for cancer treatment (Almåsbak, Aarvak, & Vemuri, ; Eshhar, ; Kalos, ; H. Liu et al, ; Lu et al, ; Smith, Oertle, Warren, & Prato, ). One of the primary considerations in designing genetically modified T cells is selecting a tumor‐restricted target (Smith et al, ).…”